When to operate? ovarian cancer trial tests best time for surgery after chemo
NCT ID NCT03579394
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial studied 211 women with advanced ovarian cancer who were not candidates for upfront surgery. Researchers compared having surgery after 3 rounds of chemotherapy versus after 6 rounds. The goal was to see which timing leads to longer disease-free survival. All patients received standard carboplatin and paclitaxel chemo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Carboplatin and paclitaxel chemotherapy followed by interval debulking surgery
- What this could lead to
- If successful, this could help doctors decide the best timing for surgery after chemotherapy to improve how long patients stay free of ovarian cancer.
- What could go wrong
- This is a completed trial, but it only looked at timing of surgery, not a new drug. Results may not apply to all ovarian cancer types or stages.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Grenoble-Alpes - Site Nord (La Tronche)
Grenoble, 38043, France
-
CHU de BREST - Hôpital Cavale Blanche
Brest, 29200, France
-
CHU de Limoges - Hôpital de la Mère et de l'Enfant
Limoges, 87000, France
-
Centre Antoine Lacassagne
Nice, 06189, France
-
Centre François Baclesse
Caen, 14000, France
-
Centre Georges François Leclerc
Dijon, 21079, France
-
Centre Hospitalier Universitaire Bretonneau
Tours, 37000, France
-
Centre Hospitalier Universitaire Caen
Caen, 14033, France
-
Centre Jean Bernard - Clinique Victor Hugo
Le Mans, 72000, France
-
Centre Jean Perrin
Clermont-Ferrand, 63000, France
-
Centre Léon Bérard
Lyon, 69373, France
-
Clinique Médico-chirurgicale CHARCOT
Sainte-Foy-lès-Lyon, 69110, France
-
Groupe Hospitalier Pitié Salpétrière
Paris, 75651, France
-
Gustave Roussy
Villejuif, 94805, France
-
Hôpital Cochin
Paris, 75014, France
-
Hôpital Européen Georges Pompidou
Paris, 75015, France
-
Hôpital Privé du Confluent
Nantes, 44202, France
-
Hôpital René Huguenin, Institut Curie
Saint-Cloud, 92210, France
-
Hôpital Saint-Joseph
Marseille, 13008, France
-
Hôpital Simone Veil
Eaubonne, 95602, France
-
Hôpital de la Milétrie - Centre Hospitalier Universitaire de Poitiers
Poitiers, 86021, France
-
Hôpital du Scorff
Lorient, 56100, France
-
ICA - Polyclinique Urbain V
Avignon, 84000, France
-
ICM Val d'Aurelle
Montpellier, 34298, France
-
ICO Centre René Gauducheau
Saint-Herblain, 44805, France
-
Institut Bergonié
Bordeau, 33076, France
-
Institut Claudius Regaud
Toulouse, 31059, France
-
Institut Jean Godinot
Reims, 51056, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can heated chemotherapy improve ovarian cancer outcomes?
- Can engineered immune cells target a common ovarian cancer protein?
- Experimental pill takes on Hard-to-Treat ovarian cancer
- Targeted drug hunts down cancer cells in advanced bladder cancer trial
- Radiation boost may Re-Sensitize ovarian cancer to PARP inhibitors
- New PET tracer could spot cancers that standard scans overlook